All Stories

  1. Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study

    Article • Current Vascular Pharmacology, September 2020, Bentham Science Publishers

    Sandro Mazzaferro, Ludovica Napoleoni